We are focused on bringing innovation to the treatment of cachexia and other muscle wasting conditions with a vision to transform care for an under-served and vulnerable patient population, prolong and improve the quality of their lives, restore their dignity and ease the burden for the patient, carer and provider.
NEWS
Sep 4, 2024
Actimed Therapeutics Announces US FDA Grant of Orphan Drug Designation to S-oxprenolol (ACM-002) for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Read more>>>
Sep 7, 2023
Actimed Therapeutics announces FDA approval of its Investigational New Drug application for Phase 2b/3 IMPACT clinical trials of S-pindolol benzoate to treat cancer cachexia
Read more>>>
Management Team
Robin Bhattacherjee

Robin Bhattacherjee

Chief Executive Officer
Frank Misselwitz

Frank Misselwitz

Chief Medical Officer and Non-executive Director
Martin Walton

Martin Walton

Chief Financial Officer
Elaine Morten

Elaine Morten

Head of Regulatory Affairs and Technical Development
Louise Bosworth

Louise Bosworth

Head of Clinical Operations and Quality

Pipeline